Global Diverticular Treatment Market

Diverticular Treatment Comprehensive Study by Type (Antibiotics Treatment, Symptomatic Treatment), Application (Diverticulosis, Diverticulitis), Indication (Symptomatic Uncomplicated Diverticular Disease, Recurrent Symptomatic Diverticular Disease, Complicated Diverticular Disease), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Drug Stores, Online Pharmacy, Others), Diagnosis (CT Scan, Ultrasound, Urine Test, Blood Test) Players and Region - Global Market Outlook to 2028

Diverticular Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Diverticular disease is a digestive disorder that causes sacs or small bulges to develop in the large intestine wall. These sacs can develop in any part of the colon, but they are most common in the sigmoid colon. Diverticular disease is caused by a variety of factors including a low-fiber diet, lack of physical activity, and some medications such as anti-inflammatory drugs, vitamin D deficiency, obesity, and smoking. The growing prevalence and recurrence of diverticular disease is expected to be the major factor driving the growth of the diverticular disease therapeutics market over the forecast period.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Market Drivers
  • Growing Prevalence and Recurrence of Diverticular Disease
  • Rise in Cigarette Smoking Population

Market Trend
  • Increase in Investment in R&D

Restraints
  • Stringent Regulatory Factors

Opportunities
Increasing Advancement in The Treatment Techniques and Launch and addition of new therapies

Diverticular Treatment Market Segmentation:
ScopeSub-Segments
Application / End UserDiverticulosis and Diverticulitis
TypeAntibiotics Treatment and Symptomatic Treatment
IndicationSymptomatic Uncomplicated Diverticular Disease,Recurrent Symptomatic Diverticular Disease,Complicated Diverticular Disease
Distribution ChannelHospital Pharmacy,Retail Pharmacies,Drug Stores,Online Pharmacy,Others
DiagnosisCT Scan,Ultrasound,Urine Test,Blood Test


Players Covered in the Study are:
Shire Plc. (United States), Cook Group Incorporated (United States), Allergan plc (Ireland), Salix Pharmaceuticals Inc. (United States), novoGI, Inc. (United States), Novartis AG (Switzerland), Glaxosmithkline Inc. (United Kingdom) and Pfizer Inc. (United States)

The Global Diverticular Treatment market is gaining huge competition due to involvement of france companies that constantly invest in research & development to meet market expectation with new innovation.

Industry Insights:
In February 2022, GlaxoSmithKline plc announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi & Co. Limited (Shionogi) as shareholders, has agreed to settle the global patent infringement litigation between GSK, Shionogi and Gilead Sciences, Inc. (Gilead) concerning ViiV Healthcare’s patents relating to dolutegravir, an antiretroviral medication used, together with other medicines, to treat human immunodeficiency virus (HIV).
I n April 2022,Emmaus Life Sciences, Inc. a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the launch of an innovative full-service telehealth solution partners, including Asembia LLC, US Bioservices Corporation and UpScriptHealth. The telehealth program capitalizes on the expansion of telemedicine in the U.S. to afford patients and providers on-line access to Endari®, the company's prescription-grade L-glutamine oral powder, for the treatment of sickle cell disease.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Diverticular Treatment Provider, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

What can be explored with Diverticular Treatment study:
• Where Diverticular Treatment industry stands in scaling its end use implementations
• What concrete benefits would result from scaled initiatives by Players
• Where Players should focus their investments cycle
• Key success factors and recommendations for upscaling future growth.
• Target Market / Country and Key Business Segments

Available Customization:
List of players that can be included in the study on immediate basis are Gilead Sciences, Inc. (United States) and Fresenius Kabi AG (Germany).


Report Objectives / Segmentation Covered

By Type
  • Antibiotics Treatment
  • Symptomatic Treatment
By Application
  • Diverticulosis
  • Diverticulitis
By Indication
  • Symptomatic Uncomplicated Diverticular Disease
  • Recurrent Symptomatic Diverticular Disease
  • Complicated Diverticular Disease

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacy
  • Others

By Diagnosis
  • CT Scan
  • Ultrasound
  • Urine Test
  • Blood Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence and Recurrence of Diverticular Disease
      • 3.2.2. Rise in Cigarette Smoking Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness
    • 3.4. Market Trends
      • 3.4.1. Increase in Investment in R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diverticular Treatment, by Type, Application, Indication, Distribution Channel, Diagnosis and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Diverticular Treatment (Value)
      • 5.2.1. Global Diverticular Treatment by: Type (Value)
        • 5.2.1.1. Antibiotics Treatment
        • 5.2.1.2. Symptomatic Treatment
      • 5.2.2. Global Diverticular Treatment by: Application (Value)
        • 5.2.2.1. Diverticulosis
        • 5.2.2.2. Diverticulitis
      • 5.2.3. Global Diverticular Treatment by: Indication (Value)
        • 5.2.3.1. Symptomatic Uncomplicated Diverticular Disease
        • 5.2.3.2. Recurrent Symptomatic Diverticular Disease
        • 5.2.3.3. Complicated Diverticular Disease
      • 5.2.4. Global Diverticular Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Drug Stores
        • 5.2.4.4. Online Pharmacy
        • 5.2.4.5. Others
      • 5.2.5. Global Diverticular Treatment by: Diagnosis (Value)
        • 5.2.5.1. CT Scan
        • 5.2.5.2. Ultrasound
        • 5.2.5.3. Urine Test
        • 5.2.5.4. Blood Test
      • 5.2.6. Global Diverticular Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Diverticular Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Shire Plc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cook Group Incorporated (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan plc (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Salix Pharmaceuticals Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. NovoGI, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Glaxosmithkline Inc. (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Diverticular Treatment Sale, by Type, Application, Indication, Distribution Channel, Diagnosis and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Diverticular Treatment (Value)
      • 7.2.1. Global Diverticular Treatment by: Type (Value)
        • 7.2.1.1. Antibiotics Treatment
        • 7.2.1.2. Symptomatic Treatment
      • 7.2.2. Global Diverticular Treatment by: Application (Value)
        • 7.2.2.1. Diverticulosis
        • 7.2.2.2. Diverticulitis
      • 7.2.3. Global Diverticular Treatment by: Indication (Value)
        • 7.2.3.1. Symptomatic Uncomplicated Diverticular Disease
        • 7.2.3.2. Recurrent Symptomatic Diverticular Disease
        • 7.2.3.3. Complicated Diverticular Disease
      • 7.2.4. Global Diverticular Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Drug Stores
        • 7.2.4.4. Online Pharmacy
        • 7.2.4.5. Others
      • 7.2.5. Global Diverticular Treatment by: Diagnosis (Value)
        • 7.2.5.1. CT Scan
        • 7.2.5.2. Ultrasound
        • 7.2.5.3. Urine Test
        • 7.2.5.4. Blood Test
      • 7.2.6. Global Diverticular Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diverticular Treatment: by Type(USD Million)
  • Table 2. Diverticular Treatment Antibiotics Treatment , by Region USD Million (2017-2022)
  • Table 3. Diverticular Treatment Symptomatic Treatment , by Region USD Million (2017-2022)
  • Table 4. Diverticular Treatment: by Application(USD Million)
  • Table 5. Diverticular Treatment Diverticulosis , by Region USD Million (2017-2022)
  • Table 6. Diverticular Treatment Diverticulitis , by Region USD Million (2017-2022)
  • Table 7. Diverticular Treatment: by Indication(USD Million)
  • Table 8. Diverticular Treatment Symptomatic Uncomplicated Diverticular Disease , by Region USD Million (2017-2022)
  • Table 9. Diverticular Treatment Recurrent Symptomatic Diverticular Disease , by Region USD Million (2017-2022)
  • Table 10. Diverticular Treatment Complicated Diverticular Disease , by Region USD Million (2017-2022)
  • Table 11. Diverticular Treatment: by Distribution Channel(USD Million)
  • Table 12. Diverticular Treatment Hospital Pharmacy , by Region USD Million (2017-2022)
  • Table 13. Diverticular Treatment Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 14. Diverticular Treatment Drug Stores , by Region USD Million (2017-2022)
  • Table 15. Diverticular Treatment Online Pharmacy , by Region USD Million (2017-2022)
  • Table 16. Diverticular Treatment Others , by Region USD Million (2017-2022)
  • Table 17. Diverticular Treatment: by Diagnosis(USD Million)
  • Table 18. Diverticular Treatment CT Scan , by Region USD Million (2017-2022)
  • Table 19. Diverticular Treatment Ultrasound , by Region USD Million (2017-2022)
  • Table 20. Diverticular Treatment Urine Test , by Region USD Million (2017-2022)
  • Table 21. Diverticular Treatment Blood Test , by Region USD Million (2017-2022)
  • Table 22. South America Diverticular Treatment, by Country USD Million (2017-2022)
  • Table 23. South America Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 24. South America Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 25. South America Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 26. South America Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 27. South America Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 28. Brazil Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 29. Brazil Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 30. Brazil Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 31. Brazil Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 32. Brazil Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 33. Argentina Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 34. Argentina Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 35. Argentina Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 36. Argentina Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 37. Argentina Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 38. Rest of South America Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 39. Rest of South America Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 40. Rest of South America Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 41. Rest of South America Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 42. Rest of South America Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 43. Asia Pacific Diverticular Treatment, by Country USD Million (2017-2022)
  • Table 44. Asia Pacific Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 45. Asia Pacific Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 46. Asia Pacific Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 47. Asia Pacific Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 48. Asia Pacific Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 49. China Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 50. China Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 51. China Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 52. China Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 53. China Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 54. Japan Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 55. Japan Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 56. Japan Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 57. Japan Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 58. Japan Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 59. India Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 60. India Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 61. India Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 62. India Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 63. India Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 64. South Korea Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 65. South Korea Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 66. South Korea Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 67. South Korea Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 68. South Korea Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 69. Taiwan Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 70. Taiwan Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 71. Taiwan Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 72. Taiwan Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 73. Taiwan Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 74. Australia Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 75. Australia Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 76. Australia Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 77. Australia Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 78. Australia Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 79. Rest of Asia-Pacific Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 80. Rest of Asia-Pacific Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 81. Rest of Asia-Pacific Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 82. Rest of Asia-Pacific Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 83. Rest of Asia-Pacific Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 84. Europe Diverticular Treatment, by Country USD Million (2017-2022)
  • Table 85. Europe Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 86. Europe Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 87. Europe Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 88. Europe Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 89. Europe Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 90. Germany Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 91. Germany Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 92. Germany Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 93. Germany Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 94. Germany Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 95. France Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 96. France Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 97. France Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 98. France Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 99. France Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 100. Italy Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 101. Italy Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 102. Italy Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 103. Italy Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 104. Italy Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 105. United Kingdom Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 106. United Kingdom Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 107. United Kingdom Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 108. United Kingdom Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 109. United Kingdom Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 110. Netherlands Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 111. Netherlands Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 112. Netherlands Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 113. Netherlands Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 114. Netherlands Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 115. Rest of Europe Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 116. Rest of Europe Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 117. Rest of Europe Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 118. Rest of Europe Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 119. Rest of Europe Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 120. MEA Diverticular Treatment, by Country USD Million (2017-2022)
  • Table 121. MEA Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 122. MEA Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 123. MEA Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 124. MEA Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 125. MEA Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 126. Middle East Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 127. Middle East Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 128. Middle East Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 129. Middle East Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 130. Middle East Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 131. Africa Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 132. Africa Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 133. Africa Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 134. Africa Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 135. Africa Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 136. North America Diverticular Treatment, by Country USD Million (2017-2022)
  • Table 137. North America Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 138. North America Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 139. North America Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 140. North America Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 141. North America Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 142. United States Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 143. United States Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 144. United States Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 145. United States Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 146. United States Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 147. Canada Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 148. Canada Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 149. Canada Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 150. Canada Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 151. Canada Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 152. Mexico Diverticular Treatment, by Type USD Million (2017-2022)
  • Table 153. Mexico Diverticular Treatment, by Application USD Million (2017-2022)
  • Table 154. Mexico Diverticular Treatment, by Indication USD Million (2017-2022)
  • Table 155. Mexico Diverticular Treatment, by Distribution Channel USD Million (2017-2022)
  • Table 156. Mexico Diverticular Treatment, by Diagnosis USD Million (2017-2022)
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Diverticular Treatment: by Type(USD Million)
  • Table 166. Diverticular Treatment Antibiotics Treatment , by Region USD Million (2023-2028)
  • Table 167. Diverticular Treatment Symptomatic Treatment , by Region USD Million (2023-2028)
  • Table 168. Diverticular Treatment: by Application(USD Million)
  • Table 169. Diverticular Treatment Diverticulosis , by Region USD Million (2023-2028)
  • Table 170. Diverticular Treatment Diverticulitis , by Region USD Million (2023-2028)
  • Table 171. Diverticular Treatment: by Indication(USD Million)
  • Table 172. Diverticular Treatment Symptomatic Uncomplicated Diverticular Disease , by Region USD Million (2023-2028)
  • Table 173. Diverticular Treatment Recurrent Symptomatic Diverticular Disease , by Region USD Million (2023-2028)
  • Table 174. Diverticular Treatment Complicated Diverticular Disease , by Region USD Million (2023-2028)
  • Table 175. Diverticular Treatment: by Distribution Channel(USD Million)
  • Table 176. Diverticular Treatment Hospital Pharmacy , by Region USD Million (2023-2028)
  • Table 177. Diverticular Treatment Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 178. Diverticular Treatment Drug Stores , by Region USD Million (2023-2028)
  • Table 179. Diverticular Treatment Online Pharmacy , by Region USD Million (2023-2028)
  • Table 180. Diverticular Treatment Others , by Region USD Million (2023-2028)
  • Table 181. Diverticular Treatment: by Diagnosis(USD Million)
  • Table 182. Diverticular Treatment CT Scan , by Region USD Million (2023-2028)
  • Table 183. Diverticular Treatment Ultrasound , by Region USD Million (2023-2028)
  • Table 184. Diverticular Treatment Urine Test , by Region USD Million (2023-2028)
  • Table 185. Diverticular Treatment Blood Test , by Region USD Million (2023-2028)
  • Table 186. South America Diverticular Treatment, by Country USD Million (2023-2028)
  • Table 187. South America Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 188. South America Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 189. South America Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 190. South America Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 191. South America Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 192. Brazil Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 193. Brazil Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 194. Brazil Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 195. Brazil Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 196. Brazil Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 197. Argentina Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 198. Argentina Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 199. Argentina Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 200. Argentina Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 201. Argentina Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 202. Rest of South America Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 203. Rest of South America Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 204. Rest of South America Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 205. Rest of South America Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 206. Rest of South America Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 207. Asia Pacific Diverticular Treatment, by Country USD Million (2023-2028)
  • Table 208. Asia Pacific Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 209. Asia Pacific Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 210. Asia Pacific Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 211. Asia Pacific Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 212. Asia Pacific Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 213. China Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 214. China Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 215. China Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 216. China Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 217. China Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 218. Japan Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 219. Japan Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 220. Japan Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 221. Japan Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 222. Japan Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 223. India Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 224. India Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 225. India Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 226. India Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 227. India Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 228. South Korea Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 229. South Korea Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 230. South Korea Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 231. South Korea Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 232. South Korea Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 233. Taiwan Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 234. Taiwan Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 235. Taiwan Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 236. Taiwan Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 237. Taiwan Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 238. Australia Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 239. Australia Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 240. Australia Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 241. Australia Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 242. Australia Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 243. Rest of Asia-Pacific Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 244. Rest of Asia-Pacific Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 245. Rest of Asia-Pacific Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 246. Rest of Asia-Pacific Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 247. Rest of Asia-Pacific Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 248. Europe Diverticular Treatment, by Country USD Million (2023-2028)
  • Table 249. Europe Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 250. Europe Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 251. Europe Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 252. Europe Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 253. Europe Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 254. Germany Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 255. Germany Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 256. Germany Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 257. Germany Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 258. Germany Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 259. France Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 260. France Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 261. France Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 262. France Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 263. France Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 264. Italy Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 265. Italy Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 266. Italy Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 267. Italy Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 268. Italy Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 269. United Kingdom Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 270. United Kingdom Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 271. United Kingdom Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 272. United Kingdom Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 273. United Kingdom Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 274. Netherlands Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 275. Netherlands Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 276. Netherlands Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 277. Netherlands Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 278. Netherlands Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 279. Rest of Europe Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 280. Rest of Europe Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 281. Rest of Europe Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 282. Rest of Europe Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 283. Rest of Europe Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 284. MEA Diverticular Treatment, by Country USD Million (2023-2028)
  • Table 285. MEA Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 286. MEA Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 287. MEA Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 288. MEA Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 289. MEA Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 290. Middle East Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 291. Middle East Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 292. Middle East Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 293. Middle East Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 294. Middle East Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 295. Africa Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 296. Africa Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 297. Africa Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 298. Africa Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 299. Africa Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 300. North America Diverticular Treatment, by Country USD Million (2023-2028)
  • Table 301. North America Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 302. North America Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 303. North America Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 304. North America Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 305. North America Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 306. United States Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 307. United States Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 308. United States Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 309. United States Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 310. United States Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 311. Canada Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 312. Canada Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 313. Canada Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 314. Canada Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 315. Canada Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 316. Mexico Diverticular Treatment, by Type USD Million (2023-2028)
  • Table 317. Mexico Diverticular Treatment, by Application USD Million (2023-2028)
  • Table 318. Mexico Diverticular Treatment, by Indication USD Million (2023-2028)
  • Table 319. Mexico Diverticular Treatment, by Distribution Channel USD Million (2023-2028)
  • Table 320. Mexico Diverticular Treatment, by Diagnosis USD Million (2023-2028)
  • Table 321. Research Programs/Design for This Report
  • Table 322. Key Data Information from Secondary Sources
  • Table 323. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diverticular Treatment: by Type USD Million (2017-2022)
  • Figure 5. Global Diverticular Treatment: by Application USD Million (2017-2022)
  • Figure 6. Global Diverticular Treatment: by Indication USD Million (2017-2022)
  • Figure 7. Global Diverticular Treatment: by Distribution Channel USD Million (2017-2022)
  • Figure 8. Global Diverticular Treatment: by Diagnosis USD Million (2017-2022)
  • Figure 9. South America Diverticular Treatment Share (%), by Country
  • Figure 10. Asia Pacific Diverticular Treatment Share (%), by Country
  • Figure 11. Europe Diverticular Treatment Share (%), by Country
  • Figure 12. MEA Diverticular Treatment Share (%), by Country
  • Figure 13. North America Diverticular Treatment Share (%), by Country
  • Figure 14. Global Diverticular Treatment share by Players 2022 (%)
  • Figure 15. Global Diverticular Treatment share by Players (Top 3) 2022(%)
  • Figure 16. Global Diverticular Treatment share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Shire Plc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Shire Plc. (United States) Revenue: by Geography 2022
  • Figure 20. Cook Group Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 21. Cook Group Incorporated (United States) Revenue: by Geography 2022
  • Figure 22. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Allergan plc (Ireland) Revenue: by Geography 2022
  • Figure 24. Salix Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Salix Pharmaceuticals Inc. (United States) Revenue: by Geography 2022
  • Figure 26. NovoGI, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. NovoGI, Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 30. Glaxosmithkline Inc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Glaxosmithkline Inc. (United Kingdom) Revenue: by Geography 2022
  • Figure 32. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 34. Global Diverticular Treatment: by Type USD Million (2023-2028)
  • Figure 35. Global Diverticular Treatment: by Application USD Million (2023-2028)
  • Figure 36. Global Diverticular Treatment: by Indication USD Million (2023-2028)
  • Figure 37. Global Diverticular Treatment: by Distribution Channel USD Million (2023-2028)
  • Figure 38. Global Diverticular Treatment: by Diagnosis USD Million (2023-2028)
  • Figure 39. South America Diverticular Treatment Share (%), by Country
  • Figure 40. Asia Pacific Diverticular Treatment Share (%), by Country
  • Figure 41. Europe Diverticular Treatment Share (%), by Country
  • Figure 42. MEA Diverticular Treatment Share (%), by Country
  • Figure 43. North America Diverticular Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Shire Plc. (United States)
  • Cook Group Incorporated (United States)
  • Allergan plc (Ireland)
  • Salix Pharmaceuticals Inc. (United States)
  • novoGI, Inc. (United States)
  • Novartis AG (Switzerland)
  • Glaxosmithkline Inc. (United Kingdom)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Gilead Sciences, Inc. (United States) , Fresenius Kabi AG (Germany)
Select User Access Type

Key Highlights of Report


Jan 2024 249 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diverticular Treatment Market Quantitative research analysis
Global Diverticular Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Diverticulosis and Diverticulitis are major end use applications of Diverticular Treatment market.
Top performing companies in the Global Diverticular Treatment market are Shire Plc. (United States), Cook Group Incorporated (United States), Allergan plc (Ireland), Salix Pharmaceuticals Inc. (United States), novoGI, Inc. (United States), Novartis AG (Switzerland), Glaxosmithkline Inc. (United Kingdom) and Pfizer Inc. (United States), to name a few.
The Concentration Rate of Global Diverticular Treatment market is highlighted using HHI Index.
"Increase in Investment in R&D" is seen as one of major influencing trends for Diverticular Treatment Market during projected period 2022-2028.
The Diverticular Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Diverticular Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Bone Infection Treatment Comprehensive Study by Type (Penicillin, Cephalosporin, Aminoglycosides, Tetracycline, Others), Route of Administration (Oral, Topical, Injectable), Distribution Channel (Hos...
$ 3450
Cell Lymphoma Treatment Comprehensive Study by Type (Oral, Injection), Types (Topical products, Systematic Products), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
$ 3500
Refractory Multiple Myeloma Treatment Comprehensive Study by Type (Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib), Cytotoxic agents, High-Dos...
$ 3750
Hypermetropia Treatment Comprehensive Study by Type (Prescription, Surgery), End-User (Hospitals, Specialty Centres, Diagnostic Centres, Clinics, Others), Laser Procedure Types (Photorefractive Kerat...
$ 3650
Canine Leptospirosis Comprehensive Study by Drug (Doxycycline, Penicillin, Ampicillin, Pfizerpen), Route of Administration (Oral, Intravenous), Distribution Channel (Veterinary hospital pharmacies, V...
$ 3450
Graves Disease Comprehensive Study by Type (Anti-Thyroid Drugs, Lodine and Iodides, Radioactive Lodine, Lonic Inhibitors), Application (Hospital, Specialty Clinics), Distribution Channel (Hospital Di...
$ 3450